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ARTICLE INFO            ABSTRACT 
 
 
 
 
Anticholinergic side effects of medications often misdiagnosed as cognitive function decline in the 
elderly. The study aims to explore the effectiveness of home medication reviews on reducing 
anticholinergic burden caused by medications with anticholinergic properties in elderly patients in 
Australia. The study was a qualitative, prospective, observational case-control study. Interviews at 
baseline and six-month were performed. Medications changes were theoretically possible to reduce 
the Anticholinergic Cognitive Burden score, but occasionally are impractical to implement. When it 
was safe to implement, recommendations were in most cases dismissed by doctors. The study could 
not draw a clear conclusion on pharmacist ability to improve older patients’ cognitive functions as the 
recommendations were not tested. The home medication review process is lacking the step that 
obligate the referring doctor to communicate the reason for not implementing the recommendations 
made by the pharmacist who needs to be addressed by Medicare. This will ensure that medication use 
is optimised.  
 
 
 
 
 
 
INTRODUCTION 
 
Many medications have anticholinergic properties that are 
unwanted. Recent studies demonstrate that the use of 
medications with anticholinergic activity increases the risk of 
cognitive function decline or impairment, especially in older 
patients (Pasina et al. 2013). A recent study in France in older 
participants (n = 544) showed that poor performance in the 
mini-mental state examination (MMSE) was highly associated 
with the use of medications with anticholinergic properties 
over one year than in non-users(Han, Agostini, and Allore 
2008). The Personnes Agees Quid (PAQUID) population study 
(n = 1780) also showed a significant association between the 
use of anticholinergic medications and the poor performance 
on the MMSE and visual memory and verbal fluency 
(Lechevallier-Michel et al. 2005). In another study (n = 3075) 
it was demonstrated that the use of anticholinergic medications 
had led to accelerated decline over six years on psychomotor 
speed, executive functioning and attention(Bottiggi et al. 
2006). The Health, Ageing, and Body composition study (n = 
3075)reported thatthe use of medications with anticholinergic 
properties was associated with poorer performance using the 
digit symbol substitution test for cognitive performance and 
continuous measure for physical function (Hilmer et al. 2007). 
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However the intensity of anticholinergic side effects depended 
on the individual response.Thus, theyare often missed, 
especially when they are mild in a patient with relatively good 
cognitive health. When they are misdiagnosed in the elderly or 
patients with a pre-existing condition like dementia, these 
effects can be serious and may lead to an increased risk of 
mortality, but can be confused with ageing or worsening of the 
preexisting condition (Tune 2001). Pharmacists can play a 
valuable role as a first point of call for over the counter 
medication and during dispensing. Effective pharmacist 
intervention can aid in reducing, managing and preventing 
medication-induced adverse events, including anticholinergic 
burden (Schnipper et al. 2006). A study showed that 
pharmacists were able to decrease the rate of preventable 
adverse drug reactions after discharge from hospital through 
patient counseling, telephone follow-up, home medication 
reviews (HMRs) and residential medication management 
reviews (RMMRs) (Schnipper et al. 2006). Additionally, 
effective collaboration between pharmacists and doctors to 
ensure optimization of medication use and patient self-
management has been shown to improve patient health literacy 
and outcomes (Eijk et al. 2001).The aim of this research wasto 
explore the effect of home medication reviewson the reduction 
of anticholinergic burden caused by medications with 
anticholinergic properties in elderly patients.  
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MATERIALS AND METHODS 
 
Design: A qualitative, prospective, observational, case-control 
study was conducted in Australia (Sydney) using data from two 
home medication review (HMR) sessions, 6-months apart. The 
HMR was unpaid and conducted for the purpose of this study. 
Patients were consented to participate. The HMRs were 
conducted by the primary researcher, female, HMR accredited 
registered pharmacist at patient homes.  Participating doctors 
were informed about the project details and what will be 
required from them verbally and in writing. Doctors were to 
identify patients who are 65 years or older, who are taking five 
medications or more, have one or more chronic medical 
conditions and are able to consent. Doctors were then to 
discuss the HMR referral with their patients and forward the 
referral to the investigator if they agree. It was made clear to 
the doctors that neither them nor the investigator will submit 
MediCare claims for the HMRs conducted for the purpose of 
this research. The methodology of the study including the 
communication cycle (Figure 1) was also discussed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There were 103 patients identified by their doctors as being 65 
years or older, with different medical conditions and multiple 
medications. Patients were then contacted by the investigator 
and the HMR interview was conducted at their homes at the 
time they elected.  In addition to conducting the HMR in 
accordance to the Pharmaceutical Society of Australia, the 
Australian Association of Consultant Pharmacists and 
MediCare guidelines, the investigator also administered 
Kessler Psychological Distress Scale 10 (K10) and Worried 
About Your Memory (WAYM) tools. The two instruments are 
designed for self-administration and no training is required. 
After the interview, and during the process of report writing, 
the anticholinergics burden (ACB) score was allocated to each 
of the medications used by the participant to calculate their 
baseline ACB total score which was later compared to their 
score at the second HMR after 6 months. The K10, WAYM 
and ACB scale are not usual part of the HMR process they are 
additional items used for the purpose of this study, with 
intention to test their usability by a pharmacist and their 
usefulness as part of the HMR process for patients above the 
age of 65 years. K10 uses a score system where WAYM uses a 
categorical dichotomous variable, no or yes answers and the 
ABC scale allocate final numerical score. The data was 
analysed categorically. Variables with high and low range were 
used as well as other variables such as the ACB scores, number 
of medications and medical conditions and were all analysed 
by age and gender. The baseline HMRwas followed by a report 
to the treating doctor with the drug optimisation 
recommendations as required by the HMR guidelines. 
Additionally, the report included the K10, WAYM results and 
the ACB score.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All occasions where the pharmacist and doctor communication 
was required were registered and an entry was made if the 
communication took place or not, its type (by phone, in person 
or in writing) and the outcome; to understand if doctors were 
prepared for this level of close collaboration. The study results 
were analysed using GSEM statistical model. 
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Figure 1. Communication Cycle 
commencement of data collection. The researcher did not 
receive HMR payment for the 103 patients included in this 
study. 
 
RESULTS  
 
The identified variables of the study are highlighted in Table 1. 
The mean value reduction in the number of medications, ACB 
score, K10 score and WAYM score variables between baseline 
and at six months were statistically significant (Table 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An in-depth analysis using a generalised structural equation 
modelling (GSEM) statistical models, showed that the ACB 
score has a significant impact on the K10 score and an indirect 
impact on the WAYM ‘yes’ outcome through the total K10 
score variables. Total K10 score can be used to potentially 
predict WAYM and vice versa. The type of medical conditions 
has been shown to affect both (Figure 2). The time taken to 
administer K10 and WAYM reduced at the six-month follow-
up from that spent at baseline. The total time taken to complete 
the HMR report including K10, WAYM and ACB score 
calculation per patient was 3 hours and 50 minutes, which 
exceeded the time used as the basis of Medicare payment for 
completion of HMR (three hours) by 50 minutes at baseline 
and by 30 minutes at the second HMR after 6 months, which is 
sustainable (Table 3). Male and female participants did not 
differ markedly in ACB scores. Females, ACB score was lower 
on average than for males by 0.14.The GSEM statistical model 
revealed that the ACB had direct and significant impact on the 
K10 score (average of 6% per individual patient), which is 
sufficient to confirm correlation, but not the causality. It was 
also found that changing the ACB by 1 point results in a 
change to the K10 total score of 0.21. This result indicates that 
ACB score reduction is likely to have a positive effect on 
patient cognitive function (statistical significance), but the 
intensity will be patient specific. However, the ACB score did 
not have a significant direct impact on the WAYM outcome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GSEM and confirmatory factor analysis (CFA) revealed that 
the gender variable appears to have a significant impact on the 
WAYM factor. Female participants also had a WAYM value 
smaller than males by 0.46 in average. Additionally, the study 
shown that WAYM results were affected by the type of 
medical conditions the participants had. If a person had; 
depression, hypercholesterolaemia, osteoporosis or arthritis the 
predicted probability for this person to have a ‘yes – (positive)’ 
WAYM outcome (i.e. memory impairment) is higher than for a 
person with any other medical condition. However, increasing 
the total K10 score resulted in a significant increase of the 
WAYM positive result. There was a relationship between 
WAYM ‘yes’ results and the total K10 scores, one of them was 
high the other was also high. Thus, either can be used to 
potentially predict the other.  
 
Table 1. List of the variables and their key properties 
 
Variable Name Variable Description Type of Variable Possible Values 
Age Age of Patient (years) Scale Range: 65–94 years 
Gender Patient Gender Categorical Female (n = 49) 
Male (n = 54) 
K10 Baseline K10 Score at Time = Baseline Scale Range: 11–55 points 
K10 6 Months K10 Score at Time = 6 Months Scale Range: 11–55 points 
WAYM Baseline WAYM Score at Time = Baseline Scale Range: 0–36 points 
WAYM 6 Months WAYM Score at Time = 6 Months Scale Range: 0–36 points 
WAYM Y/N Baseline WAYM Yes/No at Time = Baseline Categorical No 
Yes 
WAYM Y/N 6 Months WAYM Yes/No at Time = 6 Months Categorical No 
Yes 
No. Med. Conditions Number of Medical Conditions Scale Range: 1–11 Conditions 
No. Med. Conditions Group Number of Medical Conditions Group Categorical Low: 1–4 Conditions (n = 59) 
High: 5–11 Conditions (n = 44) 
ACB Baseline ACB Score at Time = Baseline Scale Range: 0–12 points 
ACB 6 Months ACB Score at Time = 6 Months Scale Range: 0–10 points 
ACB Baseline Group ACB Score at Time = Baseline Group Categorical Low: ACB Score 0–3 (n = 59) 
High: ACB Score 4–12 (n = 42) 
ACB 6 Months Group ACB Score at Time = 6 Months Group Categorical Low: ACB Score 0–3 (n = 75) 
High: ACB Score 4–12 (n = 26) 
No. Meds Baseline Number of Medications at Time = Baseline Scale Range 1–23 Medications 
No. Meds 6 Months Number of Medications at Time = 6 Months Scale Range 1–21 Medications 
No. Meds Baseline Group Number of Medications at  
Time = Baseline Group 
Categorical Low: 1–8 Medications (n = 51) 
High: 9–23 Medications (n = 52) 
No. Meds 6 Months Group Number of Medications at  
Time = 6 Months Group 
Categorical Low: 1–8 Medications (n = 53 
High: 9–23 Medications (n = 46) 
 
Table 2. Study variables at baseline and at six months 
 
Variable Baseline  6 Months Change (95% CI) 
over 6 months 
Test for Difference1 
(p-value) Mean (SD) Mean (SD) 
K10 Score 20.32 (8.9) 18.05 (8.5)  –2.27 (1.12) < 0.001** 
WAYM Score 8.34 (8.7) 7.17 (8.7)  –1.16 (0.97) 0.019* 
ACB Score 3.56 (2.5) 2.76 (1.8) –0.80 (0.23) < 0.001** 
Number of Medications 8.87 (4.6) 8.55 (4.3)  –0.32 (0.16) < 0.001** 
* Denotes statistical significance at the p < 0.05 level 
** Denotes statistical significance at the p < 0.01 level 
1The test used in each case was the ‘Paired samples t-test’. This is a more sensitive test than the ‘Independent 
samples t-test’, used elsewhere in this report 
 
 
Here, WAYM ‘yes’ has been categorised as: (0) the number of answers ‘yes’ is 
equal to 0; (1) the number of answers ‘yes’ is greater than 0. The determined 
regression coefficients are shown next to the arrows showing the direct effects 
between the considered variables with the indicated levels of statistical 
significance: (***) p < 0.001; (**) 0.001  p < 0.01; (*) 0.01  p < 0.05; () 
0.05  p < 0.1; and () 0.2 < p  0.1. Only effects with the indicated levels of 
significance are shown in this GSEM scheme 
 
Figure 2. Generalised structural equation modelling probability 
model for the two dependent variables: total K10 Scale and 
WAYM ‘yes’ 
 
Table 3. Time taken to administer the tests and prepare the 
reports 
 
Time taken (per patient) Baseline 6-month 
K10  15 minutes 10 minutes 
WAYM  15 minutes 5 minutes 
HMR interview 60 minutes 60 minutes 
Sub-total  90 minutes 75 minutes 
ACB score calculation after the 
interview 
20 minutes 15 minutes 
HMR/RMMR report  120 minutes 120 minutes 
Total  240 minutes 210 minutes 
 
Moreover, the number of medications and K10 scores were 
found to be related where a higher number of medical 
conditions was associated with greater K10 scores at six 
months.  The difference in K10 scores between the female and 
male subgroups was small. Additionally, the study revealed 
that K10 was affected by the type of medical condition 
participants had. If a person had depression, osteoporosis, 
arthritis or glaucoma the predicted total K10 value for this 
person was larger by 0.16 than for a person with any other 
medical condition. This result indicates that K10 had 
relationship with age, gender, WAYM and medical condition.  
 
DISCUSSION 
 
Communication with Doctors: Communication, collaboration 
and teamwork between doctors and pharmacists is important 
for the provision of safe and effective healthcare (Rigby 2010). 
Poor communication between doctors and pharmacists is one 
of the most important common factors resulting in medication-
related problems, including medication errors (Rigby 2010). 
This study showed that the communication between 
pharmacists and doctors was effective either at baseline or six-
month follow-up. Beside the two written communications; 
referral letter (doctor to pharmacist) and the HMR report 
(pharmacist to doctor) there were no other communication, 
which may have led to their decision on whether to accept or 
refuse pharmacists’ recommendations. It was noted that there 
was still a culture of ‘professional importance’ between doctors 
and pharmacists more than the other health professionals where 
communication regarding the HMR recommendations were not 
taking place after the submission of the report to the GP, this 
was also found to be the case in other studied (Ball, Morrissey, 
and Pilotto  2013).  This situation my improve when more 
pharmacists work at GP clinic and the HMR process be 
tailored to allow those pharmacists to conduct HMR rather than 
the current process which obligate the doctor to send their 
referral to a community pharmacy who then conduct the One 
study showed that pharmacists who reviewed patient 
medications within medical centres and in the patient’s home 
have a high rate of acceptability by patients (Chen and Britten 
2000). 
 
Using the K10 and WAYM: K-10 and WAYM were used in 
the study as tools to test the pharmacist ability to identify the 
association between cognitive function and anticholinergic 
burden and patient acceptance for the pharmacist to ask them 
those questions.The K10 and WAYM questionnaires have 
three main objectives: ‘assessing the patients’ mood and 
memory respectively; understanding the patients’ medications, 
including adverse effects and proper use and of the drugs; and 
improving patients’ health management and quality of 
life’(Andrews and Slade 2001; Worried about your memory? 
2013). The study found that through administering K10 and 
WAYM questionnaires, the pharmacist used less time at the 
six-month follow-up from that spent at baseline. This might be 
due to the patients having a better understanding of what is 
involved from their experience at the first review, or that the 
researcher became more confident and precise after practising 
at the baseline collection period, and/or that trust had been 
established. This result shows that the inclusion of K10, 
WAYM and the ABC score calculation can be sustainable if 
using an appropriate process and time management. The 
participants’ feedback indicated that they did not have 
objection of completing the K10 and WAYM assisted by a 
pharmacist. A recent survey revealed that only 14% of the 
participants distrusted pharmacists, while 60% of the 
participants trusted them, and 56% trusted doctors and 51% 
trusted dentists (Salazar 2016). At the end of the HMR visit, 
the pharmacist wrote a report to the doctors advising of the 
K10 and WAYM results, the suggestions for reducing ACB 
score caused by medications, and the potential improvement in 
the K10 and WAYM scores that could result from a change in 
medications.  
 
Patient Attitude as observed by the investigator: At first, 
during the first HMR, participants were not comfortable 
answering the questions based on their condition, but rather 
were more focused on providing the best answer. At the six-
month follow up HMR, the researcher observed that 
participants’ attitude was different and they appeared to answer 
the questions with a higher level of truthfulness as they became 
more familiar with the pharmacist communicating this type of 
issue with them. Consideration may be given by GPs to 
including the ACB, K-10 and WAYM in the GPs referral letter 
in the future for patients aged 65 years older, to better prepare 
the patient. 
 
Pharmacist Workload: The third issue is sustainability. The 
time required to administer the K10 and WAYM 
questionnaires was dependent on the individuals’ conditions 
(between 15 and 20 minutes). This suggests that HMR time 
would increase by 20 minutes to administer K10 and WAYM 
questionnaires and another ten minutes to calculate the ACB 
score. The additional 30 minutes might concern some 
pharmacists, as ‘unpaid service’, accordingly there might be 
low uptake by pharmacists; however, as it would only be for a 
certain group of patients, Medicare may be open to the idea of 
increasing the pharmacist payment  for patients over 65 years 
of age. 
 
Additional Findings: The study revealed that in some 
occasions, medication change may be identified but due to 
patient age, patient agreement to change their long-standing 
medications or other social comorbidities affecting the change 
may become impractical. The elderly have particular issues 
with drug change, due to unfamiliarity with colour, shape, 
name and the regimen of the new drug compared to the one 
they are familiar with.  Some participants mistakenly believed 
that their medical problems had been ‘adequately treated and 
drug changes could not improve their cognitionincluding 
memory problem’ (ACB03). Other patients found changing 
their medications to be ‘inconvenient, as they frequently forgot 
to take new medications’(ACB22), another did not understand 
the instructions and believed that ‘the new medication side 
effects always worse than the old one’ one: (ACB43). 
Additionally, some patients denied the possibility of 
experiencing memory problems or encountered obstacles (e.g. 
having a problem swallowing capsules or tablets, difficulty 
opening bottles). Further problems included being ‘afraid of 
dependence on the medications (C49)’, ‘being apathetic about 
becoming better without treatment (C30)’or ‘upsetting 
distrusting the doctor if they accept the changes (ACB6)’.  
 
Patient Adherence: Compared to the current literature, 
adherence in this study was found to be affected by numerous 
factors that are common amongst older people, but it was not 
affected by age itself (J. Mark Ruscin). Factors include 
polypharmacy, which is associated with a high risk of side 
effects, drug–drug interactions and problems in remembering 
when to administer each medication, and mental or physical 
impairment (J. Mark Ruscin). Moreover, older patients 
normally experience a high rate of adverse drug reactions due 
to their high sensitivity to medications resulting from 
pharmacokinetic and pharmacodynamics changes (J. Mark 
Ruscin). Older patients tend to use medications at a high rate 
due to suffering various chronic medical conditions, including 
arthritis, diabetes or Cardiovascular disease (CVD), which can 
be deteriorated by medications (J. Mark Ruscin). This study 
found that most medications taken by participants for chronic 
medical conditions had been used for years. One doctor (D01) 
did not think it worthwhile to change a medication to reduce an 
individual’s ACB score as their medical condition was stable 
and the new plan could have the potential to confuse patients 
and worsen the condition. This is also agree with the finding 
from previous study which found that effective pharmacist–
doctor collaboration in hospital setting substantially improve 
patient care (Tahaineh et al.2008). The same study highlighted 
that 48.2% of the participating doctors were uncomfortable 
with pharmacists suggesting the use of prescription 
medications to patients  (Tahaineh et al., 2008). 
 
Conclusion 
 
This study found that reduction in the number of medications, 
improvement in the K10 score, improvement in the WAYM 
score and reduction in the ACB score were possible. The study 
could not draw a clear conclusion on pharmacist ability to 
improve older patients’ cognitive functions as the 
recommendations were not implemented by the treating 
doctors. due to unavoidable factors that should be the HMR 
process is lacking the step that obligate the referring doctor to 
communicate the reason for not implementing the 
recommendations made by the pharmacist which needs to be 
addressed by Medicare to finalise the payment for both 
pharmacist and doctors. This will ensure that medication use is 
optimised. 
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